Sarepta Therapeutics, Inc.

SRPT

$17.40

Name : Sarepta Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,823,297,024.00

EPSttm : -2.83

Sarepta Therapeutics, Inc.

$17.40

3.12%

$0.56

Float Short %

22.53

Margin Of Safety %

Put/Call OI Ratio

0.85

EPS Next Q Diff

0.69

EPS Last/This Y

-4.34

EPS This/Next Y

5.1

Price

17.96

Target Price

21.43

Analyst Recom

2.77

Performance Q

Relative Volume

0.57

Beta

0.4

Ticker: SRPT

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-13	SRPT	21.43	0.82	0.48	178556
2026-01-14	SRPT	22.78	0.82	1.82	179326
2026-01-15	SRPT	21.36	0.84	5.07	181377
2026-01-16	SRPT	21.12	0.84	0.73	181225
2026-01-20	SRPT	21.03	0.86	1.54	112905
2026-01-21	SRPT	21.37	0.88	0.23	116806
2026-01-22	SRPT	21.81	0.87	1.06	117725
2026-01-23	SRPT	21.13	0.87	0.60	118362
2026-01-26	SRPT	22.79	0.86	0.34	115743
2026-01-27	SRPT	22.16	0.84	0.37	120201
2026-01-28	SRPT	21.31	0.83	0.85	121411
2026-01-29	SRPT	21.24	0.84	0.62	122020
2026-01-30	SRPT	20.32	0.83	0.48	122351
2026-02-02	SRPT	20.74	0.87	0.43	118585
2026-02-03	SRPT	20.27	0.86	0.33	119613
2026-02-05	SRPT	17.03	0.86	0.63	119540
2026-02-09	SRPT	18.31	0.86	0.36	121336
2026-02-10	SRPT	18.32	0.86	0.88	122533
2026-02-11	SRPT	17.96	0.85	1.41	123087
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-13	SRPT	21.44	-140.3	373.0	-2.00
2026-01-14	SRPT	22.81	-140.3	378.8	-2.00
2026-01-15	SRPT	21.31	-140.3	363.6	-2.00
2026-01-16	SRPT	21.12	-140.3	370.2	-2.00
2026-01-20	SRPT	21.02	-139.6	370.7	-2.00
2026-01-21	SRPT	21.38	-139.6	373.3	-2.00
2026-01-22	SRPT	21.80	-139.6	373.7	-2.00
2026-01-23	SRPT	21.13	-138.2	367.5	-2.00
2026-01-26	SRPT	22.79	-138.2	380.7	-2.00
2026-01-27	SRPT	22.16	-141.8	367.9	-2.00
2026-01-28	SRPT	21.31	-141.8	366.6	-2.00
2026-01-29	SRPT	21.24	-141.0	370.9	-2.00
2026-01-30	SRPT	20.33	-141.0	366.2	-2.00
2026-02-02	SRPT	20.73	-141.0	373.5	-2.00
2026-02-03	SRPT	20.27	-140.3	368.6	-2.00
2026-02-04	SRPT	19.72	-140.3	-	-2.00
2026-02-05	SRPT	17.03	-140.3	-	-2.00
2026-02-06	SRPT	18.50	-140.3	-	-2.00
2026-02-09	SRPT	18.30	-140.5	-	-2.00
2026-02-10	SRPT	18.32	-140.5	-	-2.00
2026-02-11	SRPT	17.96	-140.5	-	-2.00
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-13	SRPT	-0.21	3.83	20.74
2026-01-14	SRPT	-0.21	3.83	20.74
2026-01-15	SRPT	-0.21	3.83	20.74
2026-01-16	SRPT	-0.21	3.83	20.74
2026-01-20	SRPT	-0.21	4.36	20.74
2026-01-21	SRPT	-0.21	4.36	20.74
2026-01-22	SRPT	-0.21	4.36	20.74
2026-01-23	SRPT	-0.21	4.36	20.74
2026-01-26	SRPT	-0.21	2.62	20.74
2026-01-27	SRPT	-0.21	2.62	20.74
2026-01-28	SRPT	-0.21	2.62	21.57
2026-01-29	SRPT	-0.21	2.62	21.57
2026-01-30	SRPT	-0.21	2.62	21.57
2026-02-02	SRPT	-0.21	2.44	21.57
2026-02-03	SRPT	-0.21	2.44	21.58
2026-02-04	SRPT	-0.21	2.44	21.58
2026-02-05	SRPT	-0.21	2.44	21.58
2026-02-06	SRPT	-0.21	2.44	21.58
2026-02-09	SRPT	-0.21	0.47	21.58
2026-02-10	SRPT	-0.21	0.47	21.58
2026-02-11	SRPT	-0.21	0.47	22.53
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.13

Avg. EPS Est. Current Quarter

-0.7

Avg. EPS Est. Next Quarter

0.56

Insider Transactions

-0.21

Institutional Transactions

0.47

Beta

0.4

Average Sales Estimate Current Quarter

380

Average Sales Estimate Next Quarter

377

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

89.6

Max Drawdown 5-Year %

-92.7

Target Price

21.43

P/E

Forward P/E

9.31

PEG

1.65

P/S

0.78

P/B

1.43

P/Free Cash Flow

EPS

-2.89

Average EPS Est. Cur. Y

-2

EPS Next Y. (Est.)

3.1

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-11.25

Relative Volume

0.57

Return on Equity vs Sector %

-48.4

Return on Equity vs Industry %

-32.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

Sarepta Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 1372

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

stock quote shares SRPT – Sarepta Therapeutics, Inc. Stock Price stock today

news today SRPT – Sarepta Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SRPT – Sarepta Therapeutics, Inc. yahoo finance google finance

stock history SRPT – Sarepta Therapeutics, Inc. invest stock market

stock prices SRPT premarket after hours

ticker SRPT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: SRPT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y